When was T-Therapeutics founded?

T-Therapeutics was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is T-Therapeutics located?

T-Therapeutics is headquartered in Cambridge, United Kingdom.

Who is the current CEO of T-Therapeutics?

Allan Bradley of T-Therapeutics. They have also founded 2 companies.

How many employees does T-Therapeutics have?

As of Sep 30, 2026, the latest employee count at T-Therapeutics is 65.

Is T-Therapeutics a funded company?

T-Therapeutics is a funded company, having raised a total of $91.4M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 15, 2023.

When was the latest funding round of T-Therapeutics?

T-Therapeutics' latest funding was a $***** Series A round on Nov 13, 2025, with participation from 8 investors.

Where does T-Therapeutics rank among its competitors?

T-Therapeutics ranks 139th amongst 3418 active competitors, of which 1150 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of T-Therapeutics?

T-Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

T-Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of T-cell-based rtherapeutics for cancer treatment. It offers T-cell receptor-based drugs that recognise specific cancers and patient’s own T cells to kill the cancer cells and eradicate the tumour.

Website: t-therapeutics.com
Email ID: *****@t-therapeutics.com

Key Metrics

Founded Year

2022

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$91.4M in 2 rounds

Latest Funding Round

Series A, Nov 13, 2025, $*****

Investors

University of Cambridge & 7 more

Ranked

139^th among 3418 active competitors

Employee Count

65 as on Sep 30, 2026

Similar Companies

BeiGene & 816 more

View T-Therapeutics' full profile

T-Therapeutics has raised a total funding of $91.4M over 2 rounds. Its first funding round was on Nov 15, 2023. Its latest funding round was a Series A round on Nov 13, 2025 for $*****. 8 investors participated in its latest round. T-Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of T-Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2025	6351248	Series A	4605170	9493102	3300069	7213308
Nov 15, 2023	5221613	Series A	3936763	9203447	Sanofi Ventures & 5 more	5286734

Access funding benchmarks and valuations. Sign up today!

View details of T-Therapeutics's funding rounds and investors

The founders of T-Therapeutics are Allan Bradley and Haydn Prosser. Allan Bradley is the CEO of T-Therapeutics.

Here are the details of T-Therapeutics' key team members:

Allan Bradley: Co-Founder & CEO of T-Therapeutics and founder of 1 other company.
Contact Info: 1 email address
Haydn Prosser: Co-Founder & Director of T-Therapeutics.

View details of T-Therapeutics's Founder profiles and Board Members

T-Therapeutics' employee count trend

T-Therapeutics has 65 employees as of Sep 26. Here is T-Therapeutics's employee count trend over the years:

Uncover T-Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of T-Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of T-Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
139th	T-Therapeutics 2022, Cambridge (United Kingdom), Series A	Developer of T-cell-based rtherapeutics for cancer treatment	$91.4M	F-Prime Capital, Sanofi Ventures & 6 others	61/100